Clinical Trial

A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Subjects With Active Axial Spondyloarthritis Including Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis

Study acronym: BE MOVING
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of the study is to demonstrate the long-term safety, tolerability and efficacy of bimekizumab in patients with active axial spondyloarthritis (axSpA, also known as radiographic axSpa (r-axSpA)) including ankylosing spondylitis (AS) and nonradiographic axial spondyloarthritis (nr-axSpa).
Protocol Amendment History 99 amendments
This ClinicalTrials.gov record has been amended 99 times since 2020-06-15; most recent amendment 2026-07-16.
Status change: Enrolling by Invitation → Active, Not Recruiting 2023-03-07
Status change: Not Yet Recruiting → Enrolling by Invitation 2020-06-23
Trial Details
NCT Number NCT04436640
Lead Sponsor UCB Biopharma SRL
Conditions Axial Spondyloarthritis, Ankylosing Spondylitis, r-axSpa, Nr-axSpa
Enrollment 508 participants
Start Date 2020-06-16
Primary Completion 2026-08-07 (estimated)
Study Completion 2026-08-07 (estimated)
Updated on ClinicalTrials.gov 2026-08-14